With meals. In pancreatic insufficiency, dose prescribed by the doctor.
Randomized placebo-controlled trial (101 children with autism): digestive enzyme supplements improved some symptoms and behaviors, in line with the gut-brain axis hypothesis. A single trial; modest effect, to be confirmed.
View the study (study) →⏱ 3 min read
Digestive enzymes are protein catalysts that the body produces endogenously in the mouth, stomach, pancreas, and small intestine to hydrolyze dietary macronutrients (carbohydrates, proteins, fats) into smaller molecules that the intestinal epithelium can absorb; commercial digestive enzyme supplements are blends of proteases (protein digestion), lipases (fat digestion), amylases (complex carbohydrate digestion), lactase (lactose digestion), cellulase, hemicellulase, and other enzymes depending on the formulation, usually obtained by microbial fermentation (fungi such as Aspergillus oryzae, bacteria) or by extraction from porcine or bovine pancreas (pancreatin, the classic pharmaceutical formulation).
The clinical use of digestive enzymes has well-established applications in specific conditions with a documented enzyme deficiency, and more controversial applications in people without a clinical deficiency who use them because of a subjective perception of better digestion; the distinction between these two contexts is important for understanding the real indications and for not overestimating the benefits that can be expected in people with normal digestive function.
The best-established clinical indication is exocrine pancreatic insufficiency, a condition with inadequate production of pancreatic enzymes that appears in chronic pancreatitis, cystic fibrosis, advanced pancreatic cancer, total or partial pancreatectomy, and other severe pancreatic conditions; in these people, pancreatic enzyme replacement therapy (PERT) with pharmaceutical pancreatin (Creon, Pancreaze, others) is the treatment of choice, with high doses (25,000-80,000 lipase units per meal) adjusted individually to correct fat maldigestion, prevent malnutrition, and improve quality of life.
In lactose intolerance due to intestinal lactase deficiency (a very common condition that affects a large proportion of adults in many populations), supplementation with exogenous lactase taken just before meals containing lactose allows it to be digested without symptoms; it is a practical and effective solution for people who prefer not to eliminate dairy completely from their diet, with typical doses of 3,000-9,000 FCC units of lactase per meal depending on the lactose content of the meal.
In functional dyspepsia without organic pancreatic deficiency, digestive enzymes are frequently recommended (especially in integrative practice and self-administration), but rigorous clinical data are heterogeneous and of variable methodological quality; some people experience subjective improvements (especially with heavy or high-fat meals) probably attributable to a combination of a significant placebo effect, real help with the digestion of particularly difficult meals, and, in some cases, undiagnosed subclinical enzyme deficiency; reasonable expectations should be modest, and the use is probably helpful in some people with nonspecific digestive complaints, without justifying routine use in people with normal digestion.
In people on vegetarian or vegan diets who experience significant flatulence from difficulty digesting legume oligosaccharides (alpha-galactosidase), specific preparations with this enzyme (Beano and similar) significantly reduce gas formation; this is a specific indication with modest but practical clinical support.
For exocrine pancreatic insufficiency, high pharmaceutical doses regulated according to medical protocols; for lactose intolerance, 3,000-9,000 FCC units of lactase just before meals containing dairy; for flatulence from legumes, alpha-galactosidase just before the problematic meals; for general use in functional dyspepsia, multienzyme preparations tend to have variable efficacy and expectations should be modest; dosing is typically "with the first bites" of each meal so that the enzyme is present when the food bolus reaches the intestine.
Generally well tolerated at usual doses; the adverse effects described are rare and mild (mild digestive discomfort, occasionally allergic reactions in sensitive people); people with cystic fibrosis who receive very high doses of pancreatin for years may develop fibrosing colonopathy (a rare but serious complication documented in pediatrics); people with a pork allergy should avoid porcine pancreatin preparations and prefer formulations of microbial origin; those taking acarbose, miglitol, or other pharmacological alpha-glucosidase inhibitors should not take enzymes that could counteract the effect (a rare but relevant consideration); in pregnancy and breastfeeding, digestive enzymes at usual therapeutic doses are safe and well tolerated; the reasonable clinical position is: with a documented clinical deficiency (pancreatic insufficiency, lactose intolerance, specific malabsorption), specific enzyme replacement therapy is very effective; in healthy people with normal digestion, expectations of additional benefit from generic enzyme supplements are modest and often do not justify the cost of routine use.
Information, not medical advice. Scientific evidence reflects the quality of the studies.